Alto Neuroscience, Inc.
NYSE:ANROBiotechnology
+$0.40 today
- Market cap
- $1.04B
- Beta
- 1.25
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$2.26
Volume 0.99M
Average 0.34M
ANRO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Alto Neuroscience, Inc.NYSE: ANRO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$25.51M, compared with -$14.4M a year earlier. Trailing-twelve-month EBITDA was -$71.29M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +3.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$25.51M-65.1% QoQ
- Last fiscal yearDec 2025
- -$60.11M+3.5% YoY
- LTMMar 2026
- -$71.29M-16.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -77.1% | +100.0% | +177.1 pp |
| 1 year | +3.5% | +100.0% | +96.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (60.11M) USD
- Year-over-year change
- +3.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (60.11M) | +3.5% |
| FY2024 | 2024-12-31 | (62.3M) | -80.3% |
| FY2023 | 2023-12-31 | (34.56M) | -26.3% |
| FY2022 | 2022-12-31 | (27.37M) | -202.7% |
| FY2021 | 2021-12-31 | (9.04M) | — |
EBITDA vs competitors
How ANRO compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -16.9% is the 4th highest of 10, against a peer median of -29.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$5.14M USD | +92.4% | — | 2.4% | |
| LTM Mar 2026 | -$25.22M USD | +54.6% | — | — | |
| LTM Mar 2026 | -$44.93M USD | -42.6% | — | — | |
| LTM Mar 2026 | -$51.11M USD | -57.3% | — | 75.1% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | -$58.12M USD | -17.3% | — | — |
| LTM Mar 2026 | -CHF 64.45M CHF | -29.6% | — | 1740.8% | |
| LTM Mar 2026 | -$71.29M USD | -16.9% | — | — | |
| LTM Mar 2026 | -$78.13M USD | — | — | 8478.5% | |
| LTM Mar 2026 | -$78.15M USD | +14.5% | — | 2034.0% | |
| LTM Mar 2026 | -$159.48M USD | -49.1% | — | — | |
| LTM Mar 2026 | -$165.68M USD | -74.6% | — | — | |
| Peer median (excluding ANRO) | — | -29.6% | — | 1740.8% | |
Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 210K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 145K | 342K | 0 | 502K | 661K |
| Gross Profit | 65K | (342K) | 0 | (502K) | (661K) |
| Gross Margin | 31.0% | — | — | — | — |
| Research & Development | 8.37M | 23.69M | 30.29M | 47M | 45.62M |
| Selling, General & Admin | 3.75M | 5.16M | 7.52M | 21.61M | 20.75M |
| Operating Expenses | 12.12M | 28.85M | 37.81M | 68.11M | 65.7M |
| Depreciation & Amortization | 145K | 342K | 373K | 502K | 661K |
| EBITDA | (9.04M) | (27.37M) | (34.56M) | (62.3M) | (60.11M) |
| EBITDA Margin | -4305.7% | — | — | — | — |
| Operating Income | (12.06M) | (29.19M) | (37.81M) | (68.61M) | (66.36M) |
| Operating Margin | -5741.0% | — | — | — | — |
| Interest Income | 2K | 114K | 2.35M | 8.85M | 6.6M |
| Interest Expense | 0 | 0 | 1.37M | (1.38M) | 2.47M |
| Other Income / Expenses | 2.87M | 1.48M | 1.5M | 7.18M | 3.13M |
| Income Before Tax | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Pre-Tax Margin | -4374.8% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Net Margin | -4374.8% | — | — | — | — |
| EPS (Basic) | (0.36) | (1.08) | (1.35) | (2.50) | (2.19) |
| EPS (Diluted) | (0.36) | (1.08) | (1.35) | (2.50) | (2.19) |
| Weighted Avg Shares | 25.57M | 25.57M | 26.88M | 24.6M | 28.85M |
| Weighted Avg Shares (Diluted) | 25.57M | 25.57M | 26.88M | 24.6M | 28.85M |
Alto Neuroscience, Inc.
NYSE:ANRO
Intrinsic Alpha fair value
Locked
Current Price
$25.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.